Oncolytics Aligns with FDA on Registrational Path for Pelareorep in Colorectal Cancer
ONCY is trading near its 52-week low of $0.73 (14% above the low) on light trading volume (0.4× avg).
Summary
Oncolytics received FDA written feedback aligning on a potential pivotal Part B expansion of its REO 033 colorectal cancer study, offering a potential accelerated approval pathway based on objective response rate and progression-free survival.
Updates
· Reuters — The FDA alignment follows rapid site activation in the trial and comes amid going concern doubts and a Nasdaq delisting notice.
Key Events · Product Development and Regulatory · ONCY
-
FDA Alignment on Pivotal Path
FDA written feedback supports a potential pivotal Part B expansion of the ongoing REO 033 study in second-line RAS-mutant MSS colorectal cancer.
-
Accelerated Approval Potential
Proposed pathway offers potential accelerated approval based on objective response rate, with progression-free survival supporting full approval.
-
Regulatory Strategy Shift
Company elected to forego its scheduled Type D meeting and pursue an End-of-Phase meeting with the FDA as the program advances.
-
Next Milestone
Oncolytics plans to launch Part B start-up activities as soon as positive interim Part A data are available, minimizing time to pivotal expansion.
Analysis · ONCY · Life Sciences
The FDA's written feedback validates a potential accelerated approval pathway for pelareorep in second-line RAS-mutant MSS colorectal cancer. This is a major regulatory milestone that could significantly shorten the path to market for the company's lead asset. The company can now plan a pivotal Part B expansion of the ongoing REO 033 study, with objective response rate supporting accelerated approval and progression-free survival supporting full approval. This de-risks the clinical development program and provides a clear regulatory roadmap, which is especially critical given the company's going concern status and recent Nasdaq delisting notice.
How filings like this one have moved
In the 30 days to Nov 1, 2026, 40.1% of the 1118 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.35%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ONCY was trading at $0.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $104.9M. The 52-week trading range was $0.73 to $1.51. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.